- Pimodivir
-
- $31.00 / 1mg
-
2026-05-13
- CAS:1629869-44-8
- Min. Order:
- Purity: 99.99%
- Supply Ability: 10g
|
| | Pimodivir Basic information |
| Product Name: | Pimodivir | | Synonyms: | Pimodivir;Pimodivir (VX-787);VX-787;(2S,3S)-3-[[5-Fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-pyrimidinyl]amino]bicyclo[2.2.2]octane-2-carboxylic acid;CS-2483;VRT 0928787;VRT0928787;VRT-0928787 | | CAS: | 1629869-44-8 | | MF: | C20H19F2N5O2 | | MW: | 399.39 | | EINECS: | | | Product Categories: | | | Mol File: | 1629869-44-8.mol |  |
| | Pimodivir Chemical Properties |
| density | 1.501±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO, not in water:100.0(Max Conc. mg/mL);250.38(Max Conc. mM) | | form | A solid | | pka | 4.32±0.40(Predicted) | | color | White to light yellow | | InChIKey | JGPXDNKSIXAZEQ-SBBZOCNPSA-N | | SMILES | C12CCC(CC1)[C@H](NC1C(F)=CN=C(C3C4=CC(F)=CN=C4NC=3)N=1)[C@H]2C(O)=O |
| | Pimodivir Usage And Synthesis |
| Description | Pimodivir is an inhibitor of influenza virus polymerase basic protein 2 (PB2; KD = <0.003 μM). It also binds to glycogen synthase kinase 3β (GSK3β; Ki = ~1.6 μM) and inhibits the activity of Axl and calcium/calmodulin-dependent protein kinase IIβ (CaMKIIβ) by greater than 50% in a panel of 65 human and rat kinases. Pimodivir decreases the replication of seven adamantine- and neuraminidase inhibitor-resistant strains of influenza virus A (EC50s = <0.15-2.8 nM in a cell-based assay). It increases the antiviral activity of oseltamivir , zanamivir , and favipiravir (T-705; ) with 50% combination index (CI50) values of 0.58, 0.64, and 0.89, respectively, in a cell-based assay. Pimodivir increases survival in a mouse model of intranasal influenza A infection when administered at doses of 1, 3, and 10 mg/kg twice per day. | | Uses | Pimodivir is an orally bioavailable azaindole inhibitor of influenza PB2. | | in vivo | Pimodivir (2, 6, and 20 mg/kg/day, p.o.) and GS 4071 (20 mg/kg/day) completely prevent death in the H1N1pdm virus infection in mice. Pimodivir (20 mg/kg/day) is more effective than GS 4071 (20 mg/kg/day) in improving body weight and reducing the severity of lung infection[1].
Moreover, Pimodivir (VX-787) shows 100% survival in a +48 h delay to treatment mouse influenza model at 10, 3 and 1 mpk (BID × 10 days) whereas the SOC, GS 4071, provide no survival benefit in this model at 10 mpk[3].
Pimodivir (VX-787; 1, 3, or 10 mg/kg, bid) provided complete survival, with a dose-dependent reduction in BW loss of the mice[4].
| | References | [1] MICHAEL P. CLARK*. Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2[J]. Journal of Medicinal Chemistry, 2014, 57 15: 6668-6678. DOI: 10.1021/jm5007275
[2] RANDAL A BYRN. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.[J]. Antimicrobial Agents and Chemotherapy, 2015: 1569-1582. DOI: 10.1128/aac.04623-14 |
| | Pimodivir Preparation Products And Raw materials |
|